Cargando…

1969. Comparison of Adverse Event Rates Between Patients Treated With Ceftaroline or Ceftriaxone

BACKGROUND: At the VA St. Louis Health Care System 17.3% of patients treated with ceftaroline developed an adverse drug reaction (ADR). This evaluation compares ADR rates between patients treated with ceftaroline and those treated with ceftriaxone. METHODS: This was a retrospective, single-center co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Jeffrey W, Linneman, Travis W, Tan, Xing, Moenster, Ryan P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254754/ http://dx.doi.org/10.1093/ofid/ofy210.1625

Ejemplares similares

1977. Comparative Effectiveness of Linezolid vs. Trimethoprim–Sulfamethoxazole for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) at a Veterans Affairs Hospital
por: Tan, Xing, et al.
Publicado: (2018)

Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin vs. Non-Vancomycin Anti-MRSA Therapy
por: Stoneking, Carolyn, et al.
Publicado: (2017)

1424. Association Between Erythrocyte Sedimentation Rate (ESR) Change and Treatment Failure in Patients with Osteomyelitis
por: Pearson, Christopher D, et al.
Publicado: (2019)

231. Retrospective Comparison of Intravenous Therapy, Oral Therapy, and Lipoglycopeptides for the Treatment of Osteomyelitis
por: Stumphauzer, Alex, et al.
Publicado: (2021)

334. Treatment Duration of Antibiotics for Sacral Osteomyelitis After Skin Flap Procedure
por: Frye, Emily, et al.
Publicado: (2020)

109. Impact of Accelerate Pheno(TM) System on Time to De-escalation of Antimicrobial Therapy
por: Powers, Caroline, et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1559. Ertapenem Plus Ceftriaxone or Ceftaroline Dual Β-Lactam Combination for Enterococcus faecalis
por: Cusumano, Jaclyn A, et al.
Publicado: (2019)

1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
por: Holzum, Dorothy, et al.
Publicado: (2019)

101. Serious Adverse Event Rates for Cefazolin and Ceftriaxone Outpatient Parenteral Antimicrobial Therapy
por: Sunagawa, Shawnalyn, et al.
Publicado: (2023)

1045 Linezolid Compared to Daptomycin for the Treatment of Vancomycin-resistant Enterococcal Urinary Tract Infections
por: Moenster, Ryan P., et al.
Publicado: (2014)

1522. Penicillin plus ceftaroline against Enterococcus faecalis blood isolates lacking ampicillin plus ceftriaxone activity
por: Nwoye, Angella, et al.
Publicado: (2022)

1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible Streptococcus pneumoniae from the United States (2008-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

Clinical Outcomes of Antipseudomonal vs. Non-Antipseudomonal Therapy in Patients with Osteomyelitis
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Treatment Outcomes and Adverse Drug Reactions Associated with Ceftaroline Use
por: Blumenthal, Kimberly, et al.
Publicado: (2015)

2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized, Non-ICU Patients
por: Murter, Forrest, et al.
Publicado: (2019)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

370. The comparison of adverse events in combination with double beta-lactam antimicrobials: Ampicillin plus Ceftriaxone and Ampicillin/Cloxacillin with bloodstream infections
por: Ishikawa, Kazuhiro, et al.
Publicado: (2023)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

1463. Comparative Evaluation of Adverse Tendon Events Between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin Among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia
por: Patel, Nimish, et al.
Publicado: (2018)

2309. Ceftaroline for Central Nervous System and Ocular Infections
por: Siegrist, Emily A, et al.
Publicado: (2022)

2793. Clinical Outcomes of Combination Therapy with Daptomycin and Ceftaroline for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Chapin, Ryan W, et al.
Publicado: (2023)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

2527. Impact of Hypoalbuminemia on Clinical Outcomes Among Patients with Obesity Treated with Ceftriaxone
por: Rivera (O'Connor), Christina G, et al.
Publicado: (2023)

204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021)

Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
por: Srinivasan, Aswin, et al.
Publicado: (2021)

786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection?
por: Dousa, Khalid M, et al.
Publicado: (2018)

1064. Clinical Outcomes of Daptomycin in Combination With Ceftaroline or Anti-Staphylococcal Penicillins for Patients With Persistent MRSA Bacteremia
por: Bouchard, Jeannette, et al.
Publicado: (2018)

2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
por: Bouchard, Jeannette, et al.
Publicado: (2018)

1543. Ceftaroline Model-based Dose Individualization in an Infant with Kidney Disease and Mediastinitis
por: Murphy, Mark, et al.
Publicado: (2019)

215. Shorter vs. Longer Duration of Treatment in Patients with Ceftriaxone-resistant and Ceftriaxone-susceptible Escherichia coli Bloodstream Infections
por: Mackow, Natalie A, et al.
Publicado: (2023)

472 Ceftaroline-induced Neutropenia: Two Case Reports
por: Martin, Kelly E., et al.
Publicado: (2014)

1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021)

187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021)

1647. Clinical Outcomes in Pediatric Appendectomy Patients Treated with Piperacillin-Tazobactam versus Ceftriaxone/Metronidazole
por: Cosimi, Reese, et al.
Publicado: (2023)

In vitro Activity of Ceftaroline Against Pathogens Collected Globally from the AWARE Surveillance Program, 2016
por: Hackel, Meredith, et al.
Publicado: (2017)

1062. Daptomycin/Ceftaroline in Combination vs. Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Fox, Matthew, et al.
Publicado: (2018)

2426. Ceftaroline-Associated Neutropenia: Retrospective Study and Systematic Review of Incidence, Risk Factors, and Outcomes
por: Sullivan, Eva, et al.
Publicado: (2018)

1367. Reduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s HospitalReduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s Hospital
por: Sommer, Lauren, et al.
Publicado: (2020)

276. Comparison of Ceftaroline in Combination with Either Vancomycin or Daptomycin for the Treatment of Methicillin-resistant Staphylococcus aureus Bacteremia
por: Welch, Stephanie N, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_trtp4grs3jffsctqm7mklkrggs